MCID: THY023
MIFTS: 68

Thymoma

Categories: Cancer diseases, Endocrine diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Thymoma

Summaries for Thymoma

Disease Ontology : 12 A thymus cancer that derives from epithelial cells located in the thymus. The tumor cells in a thymoma look similar to the normal cells of the thymus, grow slowly, and rarely spread beyond the thymus.

MalaCards based summary : Thymoma, also known as thymus neoplasms, is related to thymoma, familial and spindle cell thymoma. An important gene associated with Thymoma is KIT (KIT Proto-Oncogene, Receptor Tyrosine Kinase), and among its related pathways/superpathways are Activation of cAMP-Dependent PKA and Class I MHC mediated antigen processing and presentation. The drugs Prednisone and Azathioprine have been mentioned in the context of this disorder. Affiliated tissues include thymus, t cells and thyroid, and related phenotypes are neoplasm of the thymus and abnormality of the mediastinum

Wikipedia : 77 A thymoma is a tumor originating from the epithelial cells of the thymus that may be benign or... more...

Related Diseases for Thymoma

Diseases in the Thymoma family:

Thymoma, Familial Invasive Malignant Thymoma
Type C Thymoma Malignant Type Ab Thymoma
Malignant Type a Thymoma Thymoma Type a
Thymoma Type B Thymoma Type Ab

Diseases related to Thymoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 379)
# Related Disease Score Top Affiliating Genes
1 thymoma, familial 34.5 HRAS KIT
2 spindle cell thymoma 33.8 CD5 LCK
3 epithelial malignant thymoma 33.7 CD5 LCK
4 dendritic cell thymoma 33.7 CD5 LCK TTN
5 mixed type thymoma 33.5 CD5 KIT
6 cortical thymoma 33.3 CD2 TTN
7 myasthenia gravis 32.8 AIRE IL2 RYR1 TTN
8 thymus cancer 32.8 CD5 DNTT DPYSL5 KIT NKX2-1
9 thymic epithelial tumor 32.6 CD5 KIT
10 lymphoblastic lymphoma 30.3 CD5 DNTT PTPRC
11 follicular dendritic cell sarcoma 29.7 EVPL KIT PPL
12 myeloma, multiple 29.7 AKT1 HRAS IL2 KIT PTPRC
13 lymphoma, non-hodgkin, familial 29.7 CD5 DNTT IL2 PTPRC
14 leukemia, chronic myeloid 29.5 DNTT EVPL HRAS KIT
15 immunodeficiency with thymoma 12.4
16 invasive malignant thymoma 12.2
17 predominantly cortical thymoma 12.2
18 type c thymoma 12.2
19 encapsulated thymoma 12.2
20 combined thymoma 12.2
21 thymoma type b 12.1
22 malignant type ab thymoma 12.0
23 noninvasive malignant thymoma 12.0
24 malignant type a thymoma 12.0
25 thymoma type ab 12.0
26 thymic carcinoma 12.0
27 thymoma type a 12.0
28 good syndrome 11.9
29 thymoma, childhood 11.9
30 pure red-cell aplasia 11.5
31 acquired pure red cell aplasia 11.4
32 morvan's fibrillary chorea 11.4
33 limbic encephalitis with lgi1 antibodies 11.1
34 myasthenia gravis congenital 11.0
35 maxillary sinus adenoid cystic carcinoma 10.4 IL2 KIT
36 lymphoma 10.4
37 myopathy, centronuclear, 2 10.4 RYR1 TTN
38 chromosome 14q11-q22 deletion syndrome 10.4 HRAS NKX2-1
39 lung adenoid cystic carcinoma 10.4 HRAS KIT NKX2-1
40 encephalitis 10.4
41 pemphigus 10.4
42 agammaglobulinemia 10.3
43 lupus erythematosus 10.3
44 respiratory system cancer 10.3 AKT1 HRAS NKX2-1
45 intestinal disease 10.3 AKT1 HRAS IL2
46 small cell carcinoma 10.3 KIT NKX2-1 PTPRC
47 gastrointestinal system cancer 10.3 AKT1 HRAS KIT
48 lymphatic system disease 10.3 CD5 IL2 TTN
49 fetal adenoma 10.3 CD5 HRAS NKX2-1
50 gastrointestinal system disease 10.3 AKT1 HRAS IL2 KIT

Graphical network of the top 20 diseases related to Thymoma:



Diseases related to Thymoma

Symptoms & Phenotypes for Thymoma

Human phenotypes related to Thymoma:

33 (show all 29)
# Description HPO Frequency HPO Source Accession
1 neoplasm of the thymus 33 hallmark (90%) HP:0100521
2 abnormality of the mediastinum 33 hallmark (90%) HP:0045026
3 ptosis 33 frequent (33%) HP:0000508
4 diplopia 33 frequent (33%) HP:0000651
5 dysphagia 33 frequent (33%) HP:0002015
6 fatigue 33 frequent (33%) HP:0012378
7 dyspnea 33 frequent (33%) HP:0002094
8 chest pain 33 frequent (33%) HP:0100749
9 cough 33 frequent (33%) HP:0012735
10 lymphadenopathy 33 frequent (33%) HP:0002716
11 fatigable weakness 33 frequent (33%) HP:0003473
12 interstitial pulmonary abnormality 33 frequent (33%) HP:0006530
13 arthritis 33 occasional (7.5%) HP:0001369
14 pancytopenia 33 occasional (7.5%) HP:0001876
15 hemolytic anemia 33 occasional (7.5%) HP:0001878
16 limitation of joint mobility 33 occasional (7.5%) HP:0001376
17 abnormality of the pleura 33 occasional (7.5%) HP:0002103
18 alopecia 33 occasional (7.5%) HP:0001596
19 thyroiditis 33 occasional (7.5%) HP:0100646
20 decreased antibody level in blood 33 occasional (7.5%) HP:0004313
21 nephrotic syndrome 33 occasional (7.5%) HP:0000100
22 keratoconjunctivitis sicca 33 occasional (7.5%) HP:0001097
23 xerostomia 33 occasional (7.5%) HP:0000217
24 pericarditis 33 occasional (7.5%) HP:0001701
25 myocarditis 33 occasional (7.5%) HP:0012819
26 skin rash 33 occasional (7.5%) HP:0000988
27 myositis 33 occasional (7.5%) HP:0100614
28 b lymphocytopenia 33 occasional (7.5%) HP:0010976
29 abnormality of the peritoneum 33 occasional (7.5%) HP:0002585

GenomeRNAi Phenotypes related to Thymoma according to GeneCards Suite gene sharing:

27 (show all 48)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.9 HRAS
2 Decreased viability GR00221-A-1 10.9 AKT1 AKT3 HRAS LCK AKT2 KIT
3 Decreased viability GR00221-A-2 10.9 AKT1 AKT3 HRAS LCK TTN
4 Decreased viability GR00221-A-3 10.9 AKT1 AKT3 HRAS LCK AKT2
5 Decreased viability GR00221-A-4 10.9 AKT1 AKT3 TTN AKT2
6 Decreased viability GR00301-A 10.9 AKT3 LCK AKT2 KIT
7 Decreased viability GR00342-S-1 10.9 LCK TTN
8 Decreased viability GR00342-S-3 10.9 LCK TTN AKT2
9 Decreased viability GR00402-S-2 10.9 AKT1 AKT3 HRAS LCK TTN AKT2
10 Decreased substrate adherent cell growth GR00193-A-1 10 AKT2 KIT
11 Decreased substrate adherent cell growth GR00193-A-2 10 AKT2 AKT3 KIT LCK
12 Decreased substrate adherent cell growth GR00193-A-3 10 AKT2 AKT3 LCK
13 Decreased substrate adherent cell growth GR00193-A-4 10 KIT LCK
14 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.91 KIT
15 Increased shRNA abundance (Z-score > 2) GR00366-A-106 9.91 AKT3
16 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.91 AKT2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.91 AKT2
18 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.91 AKT3
19 Increased shRNA abundance (Z-score > 2) GR00366-A-125 9.91 LCK
20 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.91 LCK
21 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.91 KIT
22 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.91 KIT
23 Increased shRNA abundance (Z-score > 2) GR00366-A-159 9.91 AKT2
24 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.91 AKT1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.91 AIRE
26 Increased shRNA abundance (Z-score > 2) GR00366-A-164 9.91 AKT3
27 Increased shRNA abundance (Z-score > 2) GR00366-A-170 9.91 KIT
28 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.91 AKT1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-185 9.91 AIRE
30 Increased shRNA abundance (Z-score > 2) GR00366-A-198 9.91 LCK
31 Increased shRNA abundance (Z-score > 2) GR00366-A-2 9.91 LCK
32 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.91 LCK
33 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.91 LCK
34 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.91 KIT
35 Increased shRNA abundance (Z-score > 2) GR00366-A-36 9.91 AKT2
36 Increased shRNA abundance (Z-score > 2) GR00366-A-39 9.91 AKT3
37 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.91 AKT1 KIT
38 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.91 AIRE
39 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.91 AKT1
40 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.91 AKT3
41 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.91 AKT1
42 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.91 AKT1
43 Increased shRNA abundance (Z-score > 2) GR00366-A-80 9.91 AIRE
44 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.91 AIRE AKT1 AKT2 AKT3 KIT LCK
45 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.91 KIT
46 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.91 KIT
47 Decreased cell migration GR00055-A-1 9.72 AKT1 AKT2 AKT3 HRAS LCK
48 Increased cell viability after pRB stimulation GR00230-A-1 9.35 AKT1 AKT2 AKT3 KIT LCK

MGI Mouse Phenotypes related to Thymoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.18 AIRE AKT1 AKT2 AKT3 DNTT HRAS
2 endocrine/exocrine gland MP:0005379 10.16 AIRE AKT1 AKT2 AKT3 HRAS IL2
3 hematopoietic system MP:0005397 10.13 AIRE AKT1 AKT2 AKT3 CD5 DNTT
4 immune system MP:0005387 10.11 AIRE AKT1 AKT2 AKT3 CD5 DNTT
5 digestive/alimentary MP:0005381 10.02 AIRE HRAS IL2 KIT NKX2-1 PTPRC
6 nervous system MP:0003631 10 AIRE AKT1 AKT2 AKT3 CD5 DPYSL5
7 neoplasm MP:0002006 9.97 AIRE AKT1 AKT2 AKT3 HRAS IL2
8 normal MP:0002873 9.8 AIRE AKT1 AKT2 AKT3 CD2 CD5
9 no phenotypic analysis MP:0003012 9.76 AIRE AKT2 CD5 HRAS IL2 KIT
10 respiratory system MP:0005388 9.32 AIRE AKT1 AKT2 HRAS IL2 KIT

Drugs & Therapeutics for Thymoma

Drugs for Thymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 145)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
2
Azathioprine Approved Phase 4 446-86-6 2265
3 Immunologic Factors Phase 4,Phase 1,Phase 2,Not Applicable
4 Immunosuppressive Agents Phase 4,Phase 2,Phase 1,Not Applicable
5 Hormone Antagonists Phase 4,Phase 3,Phase 2
6 Antimetabolites Phase 4
7 glucocorticoids Phase 4,Phase 3,Phase 2
8 Antirheumatic Agents Phase 4,Phase 1,Phase 2
9 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
10 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
11 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2
12 Hormones Phase 4,Phase 3,Phase 2,Phase 1
13 Antimetabolites, Antineoplastic Phase 4
14
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
15
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 441203 84093 2767
16
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
17
Prednisolone Approved, Vet_approved Phase 3,Phase 2 50-24-8 5755
18
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2 83-43-2 6741
19
Methylprednisolone hemisuccinate Approved Phase 3,Phase 2 2921-57-5
20
Prednisolone phosphate Approved, Vet_approved Phase 3,Phase 2 302-25-0
21 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
22
Prednisolone hemisuccinate Experimental Phase 3,Phase 2 2920-86-7
23 Liver Extracts Phase 3,Phase 1,Phase 2
24 Cola Phase 3,Phase 2,Phase 1,Not Applicable
25 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
26 Etoposide phosphate Phase 3,Phase 2,Phase 1
27 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
28 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
29 Anesthetics, Intravenous Phase 3
30 Central Nervous System Depressants Phase 3,Not Applicable
31 Narcotics Phase 3
32 Anesthetics, General Phase 3
33 Adjuvants, Anesthesia Phase 3
34 Analgesics, Opioid Phase 3
35 Analgesics Phase 3,Phase 1,Phase 2
36 Anesthetics Phase 3,Not Applicable
37 Methylprednisolone Acetate Phase 3,Phase 2
38 Prednisolone acetate Phase 3,Phase 2
39
Pembrolizumab Approved Phase 2,Phase 1 1374853-91-4
40
Carboplatin Approved Phase 2,Phase 1 41575-94-4 38904 10339178 498142
41
Melphalan Approved Phase 2,Not Applicable 148-82-3 460612 4053
42
Pasireotide Approved Phase 2 396091-73-9 9941444
43
Octreotide Approved, Investigational Phase 2 83150-76-9 6400441 383414
44
Belinostat Approved, Investigational Phase 2,Phase 1 866323-14-0
45
Bevacizumab Approved, Investigational Phase 2 216974-75-3
46
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
47
leucovorin Approved Phase 2,Phase 1 58-05-9 6006 143
48
Pemetrexed Approved, Investigational Phase 2,Phase 1 150399-23-8, 137281-23-3 60843 446556
49
rituximab Approved Phase 1, Phase 2 174722-31-7 10201696
50
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 6055-19-2, 50-18-0 2907

Interventional clinical trials:

(show top 50) (show all 101)
# Name Status NCT ID Phase Drugs
1 Study Comparing Two Tapering Strategies of Prednisone in Myasthenia Gravis Completed NCT00987116 Phase 4 Prednisone - Azathioprine
2 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
3 Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy Completed NCT00294658 Phase 3 prednisone alone
4 Postoperative Conformal Radiotherapy for Stage II-III B Type Thymoma Recruiting NCT02014805 Phase 3
5 Adjuvant Radiotherapy for Stage II/III Thymoma After Complete Resection Recruiting NCT02633553 Phase 3
6 Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma Recruiting NCT02633514 Phase 3 Cisplatin;Etoposide
7 A Study of Pembrolizumab for Patients With Thymic Epithelial Tumor Unknown status NCT02607631 Phase 2 Pembrolizumab
8 Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size Completed NCT02021942 Phase 2 SOM230 LAR
9 Preoperative Treatment of Patients With High Risk Thymoma Completed NCT00387868 Phase 2 cisplatin and etoposide
10 Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy Completed NCT00965250 Phase 2 IMC-12
11 Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage Completed NCT00589290 Phase 2 Belinostat (PDX101)
12 A Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat Advanced Thymoma and Thymic Cancer Completed NCT00369889 Phase 2 bevacizumab;Erlotinib
13 Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma Completed NCT00003283 Phase 2 octreotide acetate;prednisone
14 Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma Completed NCT00332969 Phase 2 Octreotide
15 Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma Completed NCT00010257 Phase 2 carboplatin;paclitaxel
16 Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma Completed NCT00198133 Phase 2 Premetrexed (Alimta)
17 Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer Completed NCT00024076 Phase 2
18 Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed NCT01369849 Phase 1, Phase 2 Akt Inhibitor MK2206;Bendamustine Hydrochloride
19 Pilot Study Of Unrelated UCB Transplant for Non-Malignant Hematologic Conditions Completed NCT00003336 Phase 2 busulfan;cyclophosphamide;melphalan;methylprednisolone
20 A Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma Completed NCT02623127 Phase 2 Sunitinib
21 High Dose Somatostatin Analogues in Neuroendocrine Tumors Completed NCT00990535 Phase 2 Octreotide-LAR
22 Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases Completed NCT00003662 Phase 2 busulfan;cyclophosphamide;cyclosporine;melphalan;methylprednisolone
23 Neoadjuvant Chemotherapy for Locally Advanced Thymic Cancer Completed NCT01312324 Phase 2 neoadjuvant docetaxel/cisplatin
24 Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults Completed NCT00376935 Phase 2 Palifermin;Palifermin placebo
25 Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity Completed NCT01163552 Phase 2
26 Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer Completed NCT00054132 Phase 2 Erlotinib Hydrochloride
27 Study of Thymosin a1 During Chemoradiotherapy For Unresectable Thymoma and Thymic Carcinoma Recruiting NCT03663764 Phase 2 Thymosin a1
28 Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM) Recruiting NCT03134118 Phase 2 Nivolumab
29 A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy Recruiting NCT03076554 Phase 2 Avelumab
30 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial) Recruiting NCT03449173 Phase 2 Sunitinib
31 Selinexor in Patients With Advanced Thymoma and Thymic Carcinoma Recruiting NCT03466827 Phase 2 Selinexor
32 Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy Recruiting NCT03193437 Phase 2 Open Label Selinexor
33 K-BASKET, TAS-117, PI3K/AKT Gene Aberration Recruiting NCT03017521 Phase 2 TAS-117
34 Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery Recruiting NCT03694002 Phase 2 Carboplatin;Paclitaxel
35 Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer Recruiting NCT03463460 Phase 2 Sunitinib Malate
36 CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis Recruiting NCT02629419 Phase 2 Amphotericin B
37 Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors Recruiting NCT03583086 Phase 1, Phase 2 VEGFR/PDGFR Dual Kinase Inhibitor X-82
38 Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies Recruiting NCT01306045 Phase 2 AZD6244;MK-2206;Lapatinib;Erlotinib;Sunitinib
39 Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy Active, not recruiting NCT02049047 Phase 2 Everolimus
40 A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas Active, not recruiting NCT02220855 Phase 2 BKM120
41 Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma Active, not recruiting NCT01025089 Phase 2 Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide
42 Sunitinib for Advanced Thymus Cancer Following Earlier Treatment Active, not recruiting NCT01621568 Phase 2 Sunitinib
43 Chemoradiotherapy for Limited Advanced Unresectable Thymic Epithelial Tumors Active, not recruiting NCT02636556 Phase 2
44 A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies Active, not recruiting NCT01364727 Phase 2 Amrubicin
45 Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma Active, not recruiting NCT02364076 Phase 2 Pembrolizumab;Epacadostat
46 Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery Active, not recruiting NCT01802320 Phase 2 Akt Inhibitor MK2206
47 Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer Active, not recruiting NCT01964924 Phase 2 Akt Inhibitor GSK2141795;Trametinib
48 A Phase II Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumor Not yet recruiting NCT03219554 Phase 2 Palbociclib
49 neoadjuvant_thymic Epithelial Tumor Not yet recruiting NCT03858582 Phase 2 pembrolizumab
50 Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum Suspended NCT02054104 Phase 1, Phase 2 Cyclophosphamide;Celecoxib

Search NIH Clinical Center for Thymoma

Cochrane evidence based reviews: thymoma

Genetic Tests for Thymoma

Anatomical Context for Thymoma

MalaCards organs/tissues related to Thymoma:

42
Thymus, T Cells, Thyroid, B Cells, Bone, Lung, Lymph Node

The Foundational Model of Anatomy Ontology organs/tissues related to Thymoma:

20
The Thymus

Publications for Thymoma

Articles related to Thymoma:

(show top 50) (show all 3037)
# Title Authors Year
1
Oral lichen planus and lichen planopilaris complicated with thymoma. ( 30758883 )
2019
2
Thoracoscopic Thymectomy for Large Thymic Cyst: Myasthenia Gravis With Thymoma Concealed by Thymic Cyst. ( 30801391 )
2019
3
Case 261: Thymoma Embedded in Thymus with Pleural Implant in Myasthenia Gravis Lambert-Eaton Overlap Syndrome. ( 30571477 )
2019
4
Altered naive CD4+ T cell homeostasis in myasthenia gravis and thymoma patients. ( 30686546 )
2019
5
Inflammatory myopathy with myasthenia gravis: Thymoma association and polymyositis pathology. ( 30697585 )
2019
6
Eculizumab improved weakness and taste disorder in thymoma-associated generalized myasthenia gravis with anti-striational antibodies: A case report. ( 30705973 )
2019
7
Acquired neuromyotonia in thymoma-associated myasthenia gravis: a clinical and serological study. ( 30714278 )
2019
8
Occurrence of acute pulmonary embolism induced by recombinant erythropoietin during treatment of pure red cell aplasia associated with thymoma: A case report. ( 30855492 )
2019
9
Case report on intravenous octreotide for the treatment of intraoperative vasoplegia following thymoma resection. ( 30800305 )
2019
10
Multilobulated thymoma with an acute angle: a new predictor of lung invasion. ( 30809718 )
2019
11
Genome‑wide DNA methylation profile of thymomas and potential epigenetic regulation of thymoma subtypes. ( 30816514 )
2019
12
Xanthomatous Thymoma. ( 30816919 )
2019
13
Paraneoplastic relapsing minimal change disease associated with type A thymoma in an elderly patient: A case report and literature review. ( 30846674 )
2019
14
Micronodular thymoma with lymphoid stroma diagnosed 10 years after the first operation: a case report. ( 30876482 )
2019
15
A previously undescribed cutaneous paraneoplastic syndrome in a cat with thymoma. ( 30908751 )
2019
16
Selected Case From the Arkadi M. Rywlin International Pathology Slide Seminar: Atypical Thymoma With Rhabdomyomatous Differentiation. ( 30300145 )
2019
17
Clinicopathologic Features of Thymoma With the Expression of Programmed Death Ligand 1. ( 30312607 )
2019
18
A novel prognostic signature of seven genes for the prediction in patients with thymoma. ( 30328513 )
2019
19
Porous diaphragm syndrome with recurrent thymoma. ( 30519470 )
2019
20
Spontaneous rupture of thymoma. ( 30533378 )
2019
21
Thymoma-associated graft-versus-host-like disease treated with high-dose i.v. immunoglobulin. ( 30656720 )
2019
22
Subxiphoid versus lateral intercostal approaches thoracoscopic thymectomy for non-myasthenic early-stage thymoma: A propensity score -matched analysis. ( 30677529 )
2019
23
Multimodality therapy for thymoma patients with pleural dissemination. ( 30725276 )
2019
24
Type B3 thymoma with marked neuroendocrine differentiation: Report of a case. ( 30746146 )
2019
25
A case of ectopic hamartomatous thymoma: controversy over the designation. ( 30778769 )
2019
26
Resected case of giant cystic thymoma with spontaneous intracystic hemorrhage. ( 30783828 )
2019
27
Lifesaving surgery for a ruptured invasive thymoma using the hemi-clamshell approach: a case report. ( 30783830 )
2019
28
Genetic characterization of thymoma. ( 30787364 )
2019
29
Spontaneous malignant myoid thymoma in an aged female Fischer 344 rat. ( 29750002 )
2018
30
Wnt4 overexpression promotes thymoma development through a JNK-mediated planar cell polarity-like pathway. ( 29387212 )
2018
31
Acquired Amegakaryocytic Thrombocytopenia and Pure Red Cell Aplasia in Thymoma. ( 29713553 )
2018
32
Abscopal effects of radiotherapy and combined mRNA-based immunotherapy in a syngeneic, OVA-expressing thymoma mouse model. ( 29335856 )
2018
33
Rapidly progressive subacute motor neuronopathy disclosing type B2 thymoma. ( 29364399 )
2018
34
Respiratory insufficiency from myasthenia gravis and polymyositis due to malignant thymoma triggering Takotsubo syndrome. ( 29883223 )
2018
35
Video-assisted thoracoscopic thymectomy for thymoma: a single-center experience. ( 29411632 )
2018
36
Anterior mediastinal leiomyosarcoma mimicking thymoma: A case report. ( 29924013 )
2018
37
Acquired amegakaryocytic thrombocytopenia and red cell aplasia in a patient with thymoma progressing to aplastic anemia successfully treated with allogenic stem cell transplantation. ( 29409729 )
2018
38
Thymoma. A Systemic Disease? ( 29801679 )
2018
39
Giant Cell Polymyositis and Myocarditis in a Patient With Thymoma and Myasthenia Gravis: A Postviral Autoimmune Process? ( 29850899 )
2018
40
Progressive multifocal leukoencephalopathy associated with thymoma with immunodeficiency: a case report and literature review. ( 29631544 )
2018
41
Comparative Analysis of V-Akt Murine Thymoma Viral Oncogene Homolog 3 <i>(AKT3)</i> Gene between Cow and Buffalo Reveals Substantial Differences for Mastitis. ( 29862252 )
2018
42
Rationale and early outcomes for the management of thymoma with proton therapy. ( 29876309 )
2018
43
Thymoma-associated multiorgan autoimmunity with exclusive gastrointestinal tract involvement: case report and review of the literature. ( 29374317 )
2018
44
Robotic-assisted thymectomy for early-stage thymoma: a propensity-score matched analysis. ( 29705833 )
2018
45
Combined operation for thymoma with myasthenia gravis and coronary artery disease in an octogenarian. ( 29924495 )
2018
46
Advanced-Stage Thymoma Associating Multiple Paraneoplastic Syndromes with Good Response to Oral Corticosteroids and Topical Tacrolimus. ( 29887166 )
2018
47
Thymoma metastasis: Differential diagnosis of pleural nodules and masses. ( 29970789 )
2018
48
Thymoma and thymic carcinoma associated with multilocular thymic cyst: a clinicopathologic analysis of 18 cases. ( 29945642 )
2018
49
Thymoma-associated myasthenia gravis and LGI1-encephalitis, with nephrotic syndrome post-thymectomy. ( 29395322 )
2018
50
Long-term survival after R0 resection of thymoma. ( 29945456 )
2018

Variations for Thymoma

ClinVar genetic disease variations for Thymoma:

6 (show all 20)
# Gene Variation Type Significance SNP ID Assembly Location
1 HRAS NM_005343.3(HRAS): c.38G> T (p.Gly13Val) single nucleotide variant Pathogenic/Likely pathogenic rs104894226 GRCh38 Chromosome 11, 534285: 534285
2 HRAS NM_005343.3(HRAS): c.38G> T (p.Gly13Val) single nucleotide variant Pathogenic/Likely pathogenic rs104894226 GRCh37 Chromosome 11, 534285: 534285
3 KIT NM_000222.2(KIT): c.1676T> C (p.Val559Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913517 GRCh37 Chromosome 4, 55593610: 55593610
4 KIT NM_000222.2(KIT): c.1676T> C (p.Val559Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913517 GRCh38 Chromosome 4, 54727444: 54727444
5 KIT NM_000222.2(KIT): c.1468G> A (p.Glu490Lys) single nucleotide variant Pathogenic rs1057519701 GRCh37 Chromosome 4, 55592144: 55592144
6 KIT NM_000222.2(KIT): c.1468G> A (p.Glu490Lys) single nucleotide variant Pathogenic rs1057519701 GRCh38 Chromosome 4, 54725978: 54725978
7 KIT NM_000222.2(KIT): c.1657T> A (p.Tyr553Asn) single nucleotide variant Pathogenic rs1057519704 GRCh37 Chromosome 4, 55593591: 55593591
8 KIT NM_000222.2(KIT): c.1657T> A (p.Tyr553Asn) single nucleotide variant Pathogenic rs1057519704 GRCh38 Chromosome 4, 54727425: 54727425
9 KIT NM_000222.2(KIT): c.1669T> C (p.Trp557Arg) single nucleotide variant Likely pathogenic rs121913235 GRCh37 Chromosome 4, 55593603: 55593603
10 KIT NM_000222.2(KIT): c.1669T> C (p.Trp557Arg) single nucleotide variant Likely pathogenic rs121913235 GRCh38 Chromosome 4, 54727437: 54727437
11 KIT NM_000222.2(KIT): c.1679_1681delTTG (p.Val560del) deletion Pathogenic/Likely pathogenic rs121913685 GRCh37 Chromosome 4, 55593612: 55593614
12 KIT NM_000222.2(KIT): c.1679_1681delTTG (p.Val560del) deletion Pathogenic/Likely pathogenic rs121913685 GRCh38 Chromosome 4, 54727447: 54727449
13 KIT NM_000222.2(KIT): c.1727T> C (p.Leu576Pro) single nucleotide variant Pathogenic/Likely pathogenic rs121913513 GRCh37 Chromosome 4, 55593661: 55593661
14 KIT NM_000222.2(KIT): c.1727T> C (p.Leu576Pro) single nucleotide variant Pathogenic/Likely pathogenic rs121913513 GRCh38 Chromosome 4, 54727495: 54727495
15 KIT NM_000222.2(KIT): c.1730_1738delCTTATGATC (p.Pro577_Asp579del) deletion Pathogenic rs1131692239 GRCh37 Chromosome 4, 55593664: 55593672
16 KIT NM_000222.2(KIT): c.1730_1738delCTTATGATC (p.Pro577_Asp579del) deletion Pathogenic rs1131692239 GRCh38 Chromosome 4, 54727498: 54727506
17 KIT NM_000222.2(KIT): c.2089C> T (p.His697Tyr) single nucleotide variant Uncertain significance rs763308199 GRCh37 Chromosome 4, 55595599: 55595599
18 KIT NM_000222.2(KIT): c.2089C> T (p.His697Tyr) single nucleotide variant Uncertain significance rs763308199 GRCh38 Chromosome 4, 54729433: 54729433
19 KIT NM_000222.2(KIT): c.2460T> A (p.Asp820Glu) single nucleotide variant Pathogenic rs1057519711 GRCh37 Chromosome 4, 55599334: 55599334
20 KIT NM_000222.2(KIT): c.2460T> A (p.Asp820Glu) single nucleotide variant Pathogenic rs1057519711 GRCh38 Chromosome 4, 54733168: 54733168

Expression for Thymoma

Search GEO for disease gene expression data for Thymoma.

Pathways for Thymoma

Pathways related to Thymoma according to GeneCards Suite gene sharing:

(show top 50) (show all 122)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.63 AKT1 AKT2 AKT3 HRAS IL2 KIT
2
Show member pathways
13.53 AKT1 AKT2 AKT3 HRAS KIT LCK
3
Show member pathways
13.48 AKT1 AKT2 AKT3 DPYSL5 EVPL HRAS
4
Show member pathways
13.47 AKT1 AKT2 AKT3 CD2 HRAS IL2
5
Show member pathways
13.36 AKT1 AKT2 AKT3 CD2 HRAS IL2
6
Show member pathways
13.34 AKT1 AKT2 AKT3 CD2 HRAS IL2
7
Show member pathways
13.29 AKT1 AKT2 AKT3 HRAS IL2 LCK
8
Show member pathways
13.1 AKT1 AKT2 AKT3 HRAS IL2 KIT
9
Show member pathways
13.07 AKT1 AKT2 AKT3 HRAS IL2 KIT
10
Show member pathways
12.99 AKT1 AKT2 AKT3 HRAS LCK PTPRC
11
Show member pathways
12.93 AKT1 AKT2 AKT3 HRAS KIT
12 12.9 AKT1 AKT2 AKT3 HRAS IL2 KIT
13
Show member pathways
12.85 AKT1 AKT2 AKT3 HRAS IL2
14 12.84 AKT1 AKT2 AKT3 HRAS KIT
15
Show member pathways
12.84 AKT1 AKT2 AKT3 HRAS KIT
16
Show member pathways
12.82 AKT1 AKT2 AKT3 HRAS RYR1
17
Show member pathways
12.8 AKT1 AKT2 AKT3 HRAS KIT
18
Show member pathways
12.76 AKT1 AKT2 AKT3 HRAS KIT LCK
19
Show member pathways
12.72 AKT1 AKT2 AKT3 HRAS NKX2-1
20
Show member pathways
12.66 AKT1 AKT2 AKT3 HRAS IL2
21
Show member pathways
12.65 AKT1 AKT2 AKT3 HRAS
22
Show member pathways
12.65 AKT1 AKT2 AKT3 HRAS PTPRC
23 12.63 CD2 IL2 KIT LCK PTPRC
24
Show member pathways
12.6 AKT1 AKT2 AKT3 HRAS IL2 LCK
25
Show member pathways
12.58 AKT1 AKT2 AKT3 HRAS LCK PTPRC
26
Show member pathways
12.56 AKT1 AKT2 AKT3 HRAS
27
Show member pathways
12.55 AKT1 AKT2 AKT3 HRAS
28
Show member pathways
12.5 AKT1 AKT2 AKT3 HRAS
29
Show member pathways
12.5 AKT1 AKT2 AKT3 HRAS
30
Show member pathways
12.49 AKT1 AKT2 AKT3 HRAS IL2
31
Show member pathways
12.47 AKT1 AKT2 AKT3 HRAS
32
Show member pathways
12.46 AKT1 AKT2 AKT3 HRAS
33
Show member pathways
12.45 AKT1 AKT2 AKT3 HRAS KIT
34
Show member pathways
12.41 AKT1 AKT2 AKT3 HRAS
35
Show member pathways
12.41 AKT1 AKT2 AKT3 HRAS RYR1
36
Show member pathways
12.4 AKT1 AKT2 AKT3 HRAS
37
Show member pathways
12.39 AKT1 AKT2 AKT3 HRAS
38
Show member pathways
12.38 AKT1 AKT2 AKT3 HRAS
39
Show member pathways
12.38 AKT1 AKT2 AKT3 IL2 LCK PTPRC
40
Show member pathways
12.37 AKT1 AKT2 AKT3 HRAS
41 12.37 AKT1 AKT2 AKT3 HRAS
42
Show member pathways
12.36 AKT1 AKT2 AKT3 HRAS LCK PTPRC
43 12.35 AKT1 AKT2 AKT3 HRAS IL2 LCK
44
Show member pathways
12.31 AKT1 AKT2 AKT3 HRAS IL2 LCK
45
Show member pathways
12.3 AKT1 AKT2 AKT3 HRAS
46
Show member pathways
12.29 AKT1 AKT2 AKT3 LCK
47
Show member pathways
12.28 AKT1 AKT2 AKT3 HRAS LCK PTPRC
48
Show member pathways
12.27 AKT1 AKT2 AKT3 HRAS
49
Show member pathways
12.27 AKT1 AKT2 AKT3 HRAS
50
Show member pathways
12.27 AKT1 AKT2 AKT3 HRAS IL2 LCK

GO Terms for Thymoma

Cellular components related to Thymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.02 CD2 CD5 KIT PTPRC THY1

Biological processes related to Thymoma according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.99 AKT1 AKT2 HRAS IL2 KIT
2 positive regulation of gene expression GO:0010628 9.88 AKT1 HRAS KIT NKX2-1 TTN
3 phosphorylation GO:0016310 9.88 AKT1 AKT2 AKT3 KIT LCK TTN
4 protein phosphorylation GO:0006468 9.8 AKT1 AKT2 AKT3 KIT LCK TTN
5 regulation of cell migration GO:0030334 9.75 AKT1 AKT2 THY1
6 positive regulation of protein phosphorylation GO:0001934 9.73 AKT1 AKT2 HRAS IL2
7 negative regulation of protein kinase activity GO:0006469 9.7 AKT1 PTPRC THY1
8 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.6 LCK THY1
9 negative regulation of protein tyrosine kinase activity GO:0061099 9.58 PTPRC THY1
10 mammary gland epithelial cell differentiation GO:0060644 9.57 AKT1 AKT2
11 positive regulation of phospholipase C activity GO:0010863 9.56 HRAS KIT
12 negative thymic T cell selection GO:0045060 9.55 AIRE PTPRC
13 positive regulation of mitochondrial membrane potential GO:0010918 9.54 AKT1 AKT2
14 T cell costimulation GO:0031295 9.54 AKT1 CD5 LCK
15 positive regulation of glucose metabolic process GO:0010907 9.51 AKT1 AKT2
16 positive regulation of isotype switching to IgG isotypes GO:0048304 9.49 IL2 PTPRC
17 peripheral nervous system myelin maintenance GO:0032287 9.46 AKT1 AKT2
18 release of sequestered calcium ion into cytosol GO:0051209 9.33 LCK PTPRC RYR1
19 negative regulation of plasma membrane long-chain fatty acid transport GO:0010748 9.26 AKT1 AKT2
20 T cell receptor signaling pathway GO:0050852 9.26 HRAS LCK PTPRC THY1
21 T cell differentiation GO:0030217 8.92 IL2 KIT LCK PTPRC

Molecular functions related to Thymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 kinase activity GO:0016301 9.73 AKT1 AKT2 AKT3 KIT LCK TTN
2 protein kinase binding GO:0019901 9.72 AKT1 LCK PTPRC THY1 TTN
3 protein binding GO:0005515 9.58 AIRE AKT1 AKT2 AKT3 CD2 CD5
4 enzyme binding GO:0019899 9.55 AKT1 NKX2-1 RYR1 THY1 TTN
5 protease binding GO:0002020 9.54 KIT RYR1 TTN
6 protein kinase activity GO:0004672 9.43 AKT1 AKT2 AKT3 KIT LCK TTN

Sources for Thymoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....